Catalent (CTLT) Lifted to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of Catalent (NYSE:CTLT) from a sell rating to a hold rating in a report issued on Tuesday morning.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
CTLT has been the subject of a number of other reports. UBS Group began coverage on Catalent in a report on Tuesday, October 9th. They set a neutral rating and a $48.00 price objective for the company. First Analysis raised Catalent from a neutral rating to an outperform rating and cut their price target for the company from $47.00 to $43.00 in a report on Wednesday, November 7th. ValuEngine cut Catalent from a buy rating to a hold rating in a report on Tuesday, November 6th. Robert W. Baird assumed coverage on Catalent in a report on Thursday, November 15th. They issued an outperform rating for the company. Finally, Morgan Stanley set a $46.00 price target on Catalent and gave the company a buy rating in a report on Monday, December 3rd. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $48.00.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.04. The company had revenue of $551.80 million during the quarter, compared to analysts’ expectations of $582.44 million. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The business’s revenue was up 1.5% on a year-over-year basis. During the same period last year, the business earned $0.21 earnings per share. On average, equities research analysts expect that Catalent will post 1.65 EPS for the current fiscal year.
In other news, SVP Lance Miyamoto sold 6,525 shares of the business’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total transaction of $277,312.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John J. Greisch bought 13,000 shares of the firm’s stock in a transaction dated Thursday, November 8th. The shares were bought at an average price of $37.61 per share, with a total value of $488,930.00. The disclosure for this purchase can be found here. Insiders own 1.40% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Diversified Trust Co grew its position in shares of Catalent by 9.1% during the 3rd quarter. Diversified Trust Co now owns 11,900 shares of the company’s stock worth $542,000 after buying an additional 995 shares during the period. Atria Investments LLC grew its position in shares of Catalent by 12.6% during the 3rd quarter. Atria Investments LLC now owns 10,208 shares of the company’s stock worth $465,000 after buying an additional 1,144 shares during the period. Retirement Systems of Alabama grew its position in shares of Catalent by 0.7% during the 4th quarter. Retirement Systems of Alabama now owns 188,448 shares of the company’s stock worth $5,876,000 after buying an additional 1,256 shares during the period. Oregon Public Employees Retirement Fund grew its position in shares of Catalent by 2.6% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 51,962 shares of the company’s stock worth $2,177,000 after buying an additional 1,299 shares during the period. Finally, State of Alaska Department of Revenue grew its position in shares of Catalent by 9.7% during the 3rd quarter. State of Alaska Department of Revenue now owns 15,648 shares of the company’s stock worth $712,000 after buying an additional 1,378 shares during the period. Institutional investors own 96.75% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: What is insider trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.